Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Severson

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Nature|December 10, 2025
Fasting boosts breast cancer therapy efficacy via glucocorticoid activationNuno Padrão, Tesa M Severson, Sebastian Gregoricchio, et al.
Haematologica|December 6, 2018
Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia across subtypesKimberly N Smitheman, Tesa M Severson, Satyajit R Rajapurkar, et al.
Oncotarget|May 3, 2018
Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects <i>in vitro</i> and poor outcome in patients with advanced head and neck squamous cell carcinomaCaroline V M Verhagen, David M Vossen, Kerstin Borgmann, et al.
Nature Communications|February 4, 2018
Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancerTesa M Severson, Yongsoo Kim, Stacey E P Joosten, et al.
Nature Communications|November 30, 2022
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potentialJeroen Kneppers, Tesa M Severson, Joseph C Siefert, et al.
Oncoimmunology|December 8, 2018
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survivalMarcelo Sobral-Leite, Koen Van de Vijver, Magali Michaut, et al.
Molecular Oncology|April 1, 2015
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platformsPhilip C Schouten, Anita Grigoriadis, Thomas Kuilman, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Nature Communications|January 25, 2020
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancerStanley Zhou, James R Hawley, Fraser Soares, et al.
Cell Reports. Medicine|July 3, 2025
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerTesa M Severson, Emma Minnee, Yanyun Zhu, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Nature|December 10, 2025
Fasting boosts breast cancer therapy efficacy via glucocorticoid activationNuno Padrão, Tesa M Severson, Sebastian Gregoricchio, et al.
Haematologica|December 6, 2018
Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia across subtypesKimberly N Smitheman, Tesa M Severson, Satyajit R Rajapurkar, et al.
Oncotarget|May 3, 2018
Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects <i>in vitro</i> and poor outcome in patients with advanced head and neck squamous cell carcinomaCaroline V M Verhagen, David M Vossen, Kerstin Borgmann, et al.
Nature Communications|February 4, 2018
Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancerTesa M Severson, Yongsoo Kim, Stacey E P Joosten, et al.
Nature Communications|November 30, 2022
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potentialJeroen Kneppers, Tesa M Severson, Joseph C Siefert, et al.
Oncoimmunology|December 8, 2018
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survivalMarcelo Sobral-Leite, Koen Van de Vijver, Magali Michaut, et al.
Molecular Oncology|April 1, 2015
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platformsPhilip C Schouten, Anita Grigoriadis, Thomas Kuilman, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Nature Communications|January 25, 2020
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancerStanley Zhou, James R Hawley, Fraser Soares, et al.
Cell Reports. Medicine|July 3, 2025
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerTesa M Severson, Emma Minnee, Yanyun Zhu, et al.
Pageof 6